62 completed, 11 terminated, 2 active not recruiting, 1 unknown. 27 Phase 3, 26 Phase 2, 20 Phase 4, 9 Phase 1, 3 Not applicable.
Follow vivitrol: new trials by email Literature Review of vivitrol trials Research Report on vivitrol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia Naltrexone (Vivitrol), Bupropion - Smoking Cessation | Phase 1 | Terminated | The University of Texas Health Science Center, Houston | 2 | 2024-07-16 | 2025-09-16 |
| Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB - Methamphetamine-dependence, Methamphetamine Abuse | Phase 3 | Active not recruiting | National Institute on Drug Abuse (NIDA) | 360 | 2024-07-01 | 2026-07-13 |
| Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep Lemborexant 10 mg, Naltrexone - Alcohol Use Disorder | Phase 3 | Completed | Baylor College of Medicine | 8 | 2023-02-09 | 2026-03-24 |
| Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 Methadone, Buprenorphine/naloxone, XR-Naltrexone - Opioid-use Disorder, HIV-1-infection | Phase 2 | Terminated | University of Pennsylvania | 78 | 2023-01-30 | 2026-04-07 |
| Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder Brixadi, Vivitrol - Opioid Dependence | Phase 2 | Terminated | University of Pennsylvania | 3 | 2022-08-01 | 2025-08-06 |
| Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections BICX104, Vivitrol - Opioid-use Disorder | Phase 1 | Completed | BioCorRx Inc | 24 | 2022-06-17 | 2023-08-16 |
| In Hospital IM Naltrexone: A Pilot Study injectable naltrexone, oral naltrexone - Alcohol Use Disorder | Phase 4 | Withdrawn | University of Colorado, Denver | 2022-03-01 | 2023-04-07 | |
| Vivitrol Treatment for Cannabis Use Disorder Naltrexone 380 MG [Vivitrol], Motivational Enhancement Therapy and Cognitive Behavioral Therapy - Cannabis Use Disorder | Phase 2 | Terminated | Centre for Addiction and Mental Health | 1 | 2021-06-09 | 2025-02-07 |
| Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) SL-BUP, XR-BUP, XR-NTX - Opioid Use Disorder (OUD) | Phase 2 | Active not recruiting | NYU Langone Health | 1516 | 2021-06-08 | 2026-11-10 |
| Impact of Colchicine and Low-dose Naltrexone on COVID-19 Colchicine 0.6 mg, Naltrexone - Covid19 | Phase 2 | Completed | HealthPartners Institute | 142 | 2021-01-25 | 2023-07-25 |
| Pharmacokinetic Study of Vivitrol in Healthy Participants Naltrexone 380 MG - Opioid-use Disorder | Phase 1 | Completed | Go Medical Industries Pty Ltd | 9 | 2021-01-25 | 2024-02-23 |
| Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults XR-B (SUBLOCADETM), XR-NTX - Opioid-use Disorder | Phase 4 | Completed | NYU Langone Health | 675 | 2021-01-07 | 2025-05-14 |
| Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder Vivitrol (Extended Release Naltrexone) - Alcohol Use Disorder, Substance Use | Phase 4 | Terminated | University of California, San Francisco | 179 | 2020-08-14 | 2023-06-22 |
| Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 Naltrexone, Ketamine, Placebo - COVID-19, Acute Respiratory Distress Syndrome | Phase 2 | Terminated | Corewell Health East | 70 | 2020-04-29 | 2022-01-26 |
| Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder XR-NTX community location - Opioid Dependence | Early Phase 1 | Completed | Michele Staton | 9 | 2019-09-11 | 2023-03-27 |
| Medication Maintenance Therapy in Community Pharmacy Settings buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care - Opioid-use Disorder | Phase 2 / Phase 3 | Unknown | Lifespan | 250 | 2019-07-25 | 2022-08-24 |
| Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD 2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks) - Post Traumatic Stress Disorder, Alcohol Abuse | Phase 2 | Terminated | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 69 | 2019-05-20 | 2023-09-14 |
| Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery Extended release naltrexone - Opioid-use Disorder | Phase 4 | Completed | Lars Tanum | 317 | 2018-08-01 | 2022-12-02 |
| Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Naltrexone for extended-release injectable suspension, Oral naltrexone - Opioid-Related Disorders | Phase 4 | Completed | Duke University | 14 | 2017-09-21 | 2020-06-16 |
| A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders Vivitrol, Buprenorphine - Opioid-use Disorder | Phase 3 | Completed | New York State Psychiatric Institute | 11 | 2017-08-01 | 2022-11-07 |
Showing 20 of 77. Sign in to see all of them.
Opioid-Related Disorders (39) · Alcoholism (23) · Substance-Related Disorders (9) · Behavior, Addictive (7) · Heroin Dependence (6) · Acquired Immunodeficiency Syndrome (3) · Amphetamine-Related Disorders (2) · COVID-19 (2) · Cocaine-Related Disorders (2) · Emergencies (2) · Inflammation (2) · Stress Disorders, Post-Traumatic (2) · Alcohol Drinking (1) · Alcohol-Related Disorders (1) · Cardiovascular Diseases (1)
Alkermes, Inc. (10) · University of Pennsylvania (9) · NYU Langone Health (8) · New York State Psychiatric Institute (8) · Yale University (5) · University of California, Los Angeles (3) · National Institute on Drug Abuse (NIDA) (2) · Oregon Health and Science University (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Baylor College of Medicine (1) · BioCorRx Inc (1) · Boston University (1) · Brown University (1) · California Pacific Medical Center Research Institute (1) · Centre for Addiction and Mental Health (1)
United States (60) · Russia (3) · Canada (2) · Norway (2) · Iceland (1) · Lithuania (1) · Netherlands (1) · Vietnam (1)
Bernard L. Silverman, MD (4) · Adam Bisaga, MD (2) · Bernard L Silverman, MD (2) · Daniel Langleben, MD (2) · George E Woody, MD (2) · John Rotrosen, MD (2) · Lars Tanum, MD, PhD (2) · Philip T Korthuis, MD, MPH (2) · Sandra A Springer, MD (2) · Adam Bisaga, M.D. (1) · Alexander Okhapkin, Prof. (1) · Alexander Sofronov, Prof. (1) · Alexey Egorov, Prof. (1) · Allison G Robertson, PhD, MPH (1)
PMID 40342086, PMID 15811981, PMID 24674234, PMID 26560326, PMID 32379516, PMID 10553740, PMID 11707638, PMID 1334156, PMID 1345133, PMID 1444726, PMID 16223067, PMID 16624967, PMID 17045423, PMID 17588491, PMID 17873686, PMID 18241321, PMID 18348601, PMID 18472999, PMID 18775624, PMID 19053979, PMID 20363090, PMID 21314752, PMID 21529928, PMID 21575016, PMID 21715107, PMID 21769033, PMID 22089316, PMID 22945623, PMID 22985676, PMID 23036218, PMID 23159524, PMID 23188075, PMID 23571420, PMID 23577900, PMID 23627868, PMID 23701526, PMID 24650044, PMID 24825644, PMID 25037206, PMID 25092008, PMID 25703440, PMID 25901451, PMID 26039070, PMID 26629534, PMID 26948856, PMID 27121539, PMID 27178765, PMID 27282118, PMID 27521809, PMID 28061017
P50DA012756 (2), R01DA010746 (2), UG1DA013035 (2), 2009 (1), 2017 (1), K02DA032322 (1), K23AA022989 (1), R01AA018923 (1), R01AA018944 (1), R01AA021335 (1), R01AA021744 (1), R01DA015822 (1), R01DA019497 (1), R01DA024549 (1), R01DA027405 (1)